Integrating the patient’s voice: A new study shows access to patient-reported outcome (PRO) data improves the consistency of the evaluation of treatment-related side effects in patients with cancer.
A widely used chemotherapy drugs used in cancer treatments can cause heart damage, new research shows. This could be used to adapt treatment regimens - especially in patients with high blood pressure.
A new study shows a significant survival benefit for patients with oropharyngeal cancers treated with proton therapy (IMPT) compared to those treated with traditional radiation therapy (IMRT).
Researchers have discovered that low physical activity is associated with a higher risk of lymphedema. They have also noted that a lymph scanner objectively measures changes in the condition.
Radiotherapy is effective against prostate cancer but can cause side effects. Using AI, scientists found that images originally taken to help position patients could also predict rectal bleeding.
A novel AI-based method can distinguish between progressive brain tumours and radiotherapy-induced necrosis on advanced MRI. This could help clinicians more accurately identify and treat the issues.
After T-cell redirecting therapies, patients are typically hospitalized for several days to watch for side effects. New research shows that these patients can safely be monitored at home.
New immunotherapies are effective against skin cancer, but they can cause serious side effects. New insights suggest that a lower dosage may lead to better outcomes and longer survival.
IDH mutated gliomas are slow-growing brain tumors with a relatively good prognosis. A new study shows that many patients reveal measurable cognitive impairment in the first year after treatment.
Most patients with metastatic colorectal cancer do not respond to immunotherapy—but why? A new study shows how the tumours block the immune system through two complementary mechanisms.
Researchers explore how ultrasound waves can be used to activate chemotherapy drugs only in targeted areas, offering a new path toward safer, more effective cancer treatment.
Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets. At the ESMO congress in Berlin, Yuting (Shelley) Liu, Head of China Business Development and Strategy of Hengrui Pharma, shared insights into how the company is translating decades of Chinese market experience into a global oncology strategy.
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, according to experts presenting at the 37th European Congress of Pathology in Vienna this September. During a session on state-of-the-art in gastrointestinal biomarkers, speakers outlined how targeted therapies and immunotherapies are transforming treatment options – but…
Underscoring the growing role of large language models (LLM) in cancer care, ESMO released the first structured set of recommendations to bring AI language models into oncology safely and effectively.
A novel imaging solution, called PSMA PET scanning, can more effectively detect the recurrence of prostate cancer compared to standard methods, and is associated with improved survival outcomes.
An expert summit for craniomaxillofacial (CMF) care brought together leading surgeons to explore how digital technologies are reshaping surgical planning, precision, and patient outcomes.
Breast cancer claims around 670.000 lives each year. Now, researchers propose that whole genome sequencing (WGS) could help many patients find better treatments or match them with clinical trials.
Precision Oncology Ireland (POI), a €28M cancer research programme uniting universities, charities and industry to develop tailored diagnostic and therapeutic solutions, has now entered phase 2.
Currently, cancer treatment evaluation focuses heavily on survival outcomes, but doesn't adequately consider how treatments affect quality of life. A new policy review aims to change this.
